{"gene":"RFXANK","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":1999,"finding":"RFXANK (RFX-B) was identified as the smallest subunit of the heterotrimeric RFX complex. It contains three ankyrin repeats but no known DNA-binding domain, and its loss-of-function mutations are responsible for the predominant bare lymphocyte syndrome (BLS) complementation group B, characterized by absence of MHC class II transcription.","method":"Protein purification, sequencing, complementation assay in BLS patient cell lines","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — protein purified and sequenced, complementation assays in disease cell lines, replicated across studies","pmids":["10072068"],"is_preprint":false},{"year":2001,"finding":"RFXANK ankyrin repeats mediate simultaneous interactions with RFXAP and CIITA on two opposite faces of the ankyrin repeat domain. RFXAP binding requires two separate surfaces on RFXANK, one located in the ankyrin groove. A BLS patient mutation (FZA) specifically disrupts the RFXAP-binding surface in the ankyrin groove without affecting CIITA binding.","method":"Computational modeling of RFXANK, site-directed alanine mutagenesis of variable ankyrin residues, in vitro and in vivo binding assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with both in vitro and in vivo binding studies, structural modeling validated by functional assays, single lab","pmids":["11463838"],"is_preprint":false},{"year":2000,"finding":"Novel mutations in RFX-B (RFXANK) were identified in BLS patient fibroblasts. Unlike RFX5- and RFXAP-deficient cells, exogenous CIITA partially rescued MHC class II (HLA-DR, HLA-DP), MHC class I, beta2-microglobulin, and invariant chain expression in RFX-B-deficient cells, suggesting CIITA can partially override RFX-B deficiency. Wild-type RFX-B expression fully reverted all noted deficiencies.","method":"Mutation analysis, CIITA transfection rescue experiments, MHC reporter assays in patient-derived fibroblasts","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complementation and rescue experiments in patient cell lines, two orthogonal methods, single lab","pmids":["10725724"],"is_preprint":false},{"year":2003,"finding":"Two novel RFXANK missense mutations (D121V and Y224A) were characterized. The D121V mutant was unable to form the RFX complex, indicating D121 is required for RFXAP binding. The Y224A mutant formed an RFX complex that bound normally to the MHC II promoter but failed to transactivate MHC class II, indicating that an aromatic ring at position 224 is needed for a function beyond promoter binding—likely interaction with an additional unknown protein via the fourth ankyrin repeat.","method":"Site-directed mutagenesis, protein interaction assays, DNA binding assays, MHC II expression analysis in patient cells","journal":"Immunogenetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with in vitro protein interaction and DNA binding assays, functional readout of MHC II expression, single lab with multiple orthogonal methods","pmids":["12618906"],"is_preprint":false},{"year":2005,"finding":"Class IIa HDACs (HDAC4 and HDAC5) physically associate with RFXANK (RFX-B/Tvl-1/ANKRA1) through its ankyrin repeat domain. HDAC4 has two RFXANK-binding sites (residues 118-279 and 448-666). Through this association, HDAC4 and HDAC5 repress MHC II promoter activation and endogenous HLA-DRA gene expression induced by CIITA. Phosphorylation of class II HDACs by CaMK results in CRM1-dependent nuclear export of HDAC/RFXANK complexes.","method":"Yeast two-hybrid screen, co-immunoprecipitation, ankyrin repeat interaction mapping, MHC II promoter reporter assays, HLA-DRA expression assays, CaMK phosphorylation and nuclear export assays","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated independently in two labs (McKinsey et al. and Wang et al., same year), reciprocal interaction mapping, functional promoter assays, and signal-responsive nuclear export mechanism established","pmids":["16236793","15964851"],"is_preprint":false},{"year":2005,"finding":"RFXANK interacts with class IIa HDAC4 through its ankyrin repeat domain. Two RFXANK-binding sites were mapped on HDAC4 (residues 118-279 and 448-666). HDAC4 also interacted with CIITA. HDAC4 and homologs repressed MHC II expression, identifying RFXANK and CIITA as novel targets of class IIa HDACs.","method":"Yeast two-hybrid screen (HDAC4 as bait), co-immunoprecipitation, deletion mapping, MHC II expression assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus co-IP with functional MHC II expression assays, single lab, consistent with independent report","pmids":["15964851"],"is_preprint":false},{"year":2011,"finding":"RFXANK gene mutations (predominantly a 26-bp founder deletion, I5E6-25_I5E6+1) account for two-thirds of all MHC class II deficiency cases. Patients have absence of MHC class II molecule expression, impaired antigen presentation to CD4+ T cells, and combined immunodeficiency. Hematopoietic stem cell transplantation restores near-normal immune function, establishing RFXANK as essential for MHC II expression in the immune system.","method":"Genetic analysis of 35 patients, immunological phenotyping, HSCT outcome analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Strong — large patient cohort with genetic and immunological characterization, but primarily clinical/genetic rather than direct mechanistic biochemical assay","pmids":["21908431"],"is_preprint":false},{"year":2000,"finding":"The 752delG-25 (26-bp deletion) mutation in RFXANK is a founder mutation of North African origin responsible for the majority of MHC class II deficiency group B patients. This mutation eliminates RFXANK function required for RFX complex assembly and MHC II transcription.","method":"Mutation analysis in 20 patients, haplotype analysis for founder effect, functional complementation","journal":"Immunogenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic analysis across multiple unrelated families, haplotype confirmation of founder effect, functional data from complementation studies in related papers","pmids":["10803838"],"is_preprint":false}],"current_model":"RFXANK (RFX-B) is a subunit of the heterotrimeric RFX transcription factor complex that nucleates assembly of multiple transcription factors (including RFX5, RFXAP, and CIITA) on MHC class II gene promoters; its ankyrin repeat domain mediates simultaneous binding of RFXAP and CIITA on opposite faces, and class IIa HDACs (HDAC4/5) associate with these ankyrin repeats to repress MHC II transcription in a CaMK-phosphorylation/nuclear-export-dependent manner, while loss-of-function RFXANK mutations cause bare lymphocyte syndrome by abolishing MHC II expression and antigen presentation."},"narrative":{"mechanistic_narrative":"RFXANK (RFX-B) is the smallest subunit of the heterotrimeric RFX transcription factor complex that governs MHC class II gene expression, and loss-of-function mutations in it cause the predominant complementation group B of bare lymphocyte syndrome through abolition of MHC class II transcription [PMID:10072068, PMID:21908431]. Although it lacks a DNA-binding domain, its three ankyrin repeats serve as a scaffold that simultaneously engages RFXAP and CIITA on opposite faces of the ankyrin repeat domain; RFXAP binding depends on a surface within the ankyrin groove, and patient mutations such as D121V abolish RFX complex assembly by disrupting RFXAP binding [PMID:11463838, PMID:12618906]. A separate function maps to the fourth ankyrin repeat: the Y224A mutant assembles an RFX complex that binds the MHC II promoter normally yet fails to transactivate, defining a transactivation step beyond promoter occupancy [PMID:12618906]. RFXANK is also a target of negative regulation, as class IIa HDACs (HDAC4 and HDAC5) associate with its ankyrin repeats and with CIITA to repress CIITA-induced MHC II and endogenous HLA-DRA expression, a repression relieved when CaMK phosphorylation drives CRM1-dependent nuclear export of the HDAC/RFXANK complex [PMID:16236793, PMID:15964851]. Functionally, RFXANK deficiency in patients eliminates MHC class II surface expression and CD4+ T cell antigen presentation, a defect correctable by hematopoietic stem cell transplantation [PMID:21908431].","teleology":[{"year":1999,"claim":"Established the molecular identity of the BLS group B gene by purifying RFXANK as the smallest RFX subunit, linking an ankyrin-repeat protein lacking DNA-binding activity to loss of MHC class II transcription.","evidence":"Protein purification, sequencing, and complementation in BLS patient cell lines","pmids":["10072068"],"confidence":"High","gaps":["Did not resolve how a DNA-binding-deficient subunit contributes to promoter function","Interaction surfaces with other RFX subunits not yet mapped"]},{"year":2000,"claim":"Defined the genetic basis of group B disease by identifying a North African founder deletion as the major RFXANK lesion abolishing RFX complex assembly.","evidence":"Mutation and haplotype analysis across patients with functional complementation","pmids":["10803838"],"confidence":"Medium","gaps":["Founder effect is genetic/epidemiological rather than direct biochemical proof of the assembly defect"]},{"year":2000,"claim":"Revealed that RFXANK deficiency is distinct from RFX5/RFXAP loss, since exogenous CIITA can partially restore MHC expression, implicating RFXANK in a CIITA-influenced step.","evidence":"CIITA transfection rescue and MHC reporter assays in patient fibroblasts","pmids":["10725724"],"confidence":"Medium","gaps":["Mechanism of partial CIITA override not defined","Single lab, patient-cell-based readouts"]},{"year":2001,"claim":"Resolved the architectural role of the ankyrin repeats, showing RFXANK uses opposite faces to bind RFXAP and CIITA simultaneously and that a patient mutation disrupts only the RFXAP-binding groove.","evidence":"Computational modeling, alanine-scanning mutagenesis, in vitro and in vivo binding assays","pmids":["11463838"],"confidence":"High","gaps":["No experimental structure of the assembled complex","Stoichiometry on the promoter not determined"]},{"year":2003,"claim":"Separated RFXANK's assembly function from its transactivation function via two missense mutants, showing D121 is needed for RFXAP binding while Y224 is dispensable for promoter binding but required for transactivation.","evidence":"Site-directed mutagenesis, protein interaction and DNA binding assays, MHC II expression analysis in patient cells","pmids":["12618906"],"confidence":"High","gaps":["The additional protein inferred to bind the fourth ankyrin repeat was not identified","Direct transactivation partner remains uncharacterized"]},{"year":2005,"claim":"Identified RFXANK as a regulatory target by showing class IIa HDAC4/HDAC5 bind its ankyrin repeats and repress CIITA-driven MHC II transcription in a CaMK-phosphorylation/CRM1-export-dependent manner.","evidence":"Yeast two-hybrid, co-immunoprecipitation, interaction mapping, promoter and HLA-DRA expression assays, CaMK/nuclear export assays","pmids":["16236793","15964851"],"confidence":"High","gaps":["Physiological signals controlling CaMK-driven repression in immune cells not defined","Whether HDAC binding competes directly with RFXAP/CIITA on the ankyrin surface not resolved"]},{"year":2011,"claim":"Consolidated RFXANK as the dominant cause of MHC class II deficiency and demonstrated that the resulting immunodeficiency is correctable, confirming RFXANK is essential for immune MHC II expression.","evidence":"Genetic and immunological analysis of 35 patients with HSCT outcome data","pmids":["21908431"],"confidence":"Medium","gaps":["Clinical/genetic rather than direct biochemical mechanism","Does not address tissue-specific roles outside the immune system"]},{"year":null,"claim":"The identity of the protein bound by the fourth ankyrin repeat that mediates RFXANK-dependent transactivation beyond promoter occupancy remains unknown.","evidence":"Inferred from the Y224A transactivation-defective phenotype","pmids":[],"confidence":"High","gaps":["No candidate partner for the transactivation step identified","No structural model of the RFXANK transactivation interface"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,3]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[1,3]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[1,4]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,3]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6]}],"complexes":["RFX complex (RFX5-RFXAP-RFXANK)"],"partners":["RFXAP","CIITA","RFX5","HDAC4","HDAC5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O14593","full_name":"DNA-binding protein RFXANK","aliases":["Ankyrin repeat family A protein 1","Regulatory factor X subunit B","RFX-B","Regulatory factor X-associated ankyrin-containing protein"],"length_aa":260,"mass_kda":28.1,"function":"Activates transcription from class II MHC promoters. Activation requires the activity of the MHC class II transactivator/CIITA. May regulate other genes in the cell. RFX binds the X1 box of MHC-II promoters (PubMed:10072068, PubMed:10725724, PubMed:9806546). May also potentiate the activation of RAF1 (By similarity) Isoform 2 is not involved in the positive regulation of MHC class II genes","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/O14593/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/RFXANK","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/RFXANK","total_profiled":1310},"omim":[{"mim_id":"620817","title":"MHC CLASS II DEFICIENCY 4; MHC2D4","url":"https://www.omim.org/entry/620817"},{"mim_id":"620816","title":"MHC CLASS II DEFICIENCY 3; MHC2D3","url":"https://www.omim.org/entry/620816"},{"mim_id":"620815","title":"MHC CLASS II DEFICIENCY 2; MHC2D2","url":"https://www.omim.org/entry/620815"},{"mim_id":"605787","title":"ANKYRIN REPEAT-CONTAINING PROTEIN, FAMILY A, MEMBER 2; ANKRA2","url":"https://www.omim.org/entry/605787"},{"mim_id":"603200","title":"REGULATORY FACTOR X, ANKYRIN REPEAT-CONTAINING; RFXANK","url":"https://www.omim.org/entry/603200"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RFXANK"},"hgnc":{"alias_symbol":["BLS","RFX-B","ANKRA1","F14150_1","MGC138628"],"prev_symbol":[]},"alphafold":{"accession":"O14593","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14593","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14593-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14593-F1-predicted_aligned_error_v6.png","plddt_mean":78.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RFXANK","jax_strain_url":"https://www.jax.org/strain/search?query=RFXANK"},"sequence":{"accession":"O14593","fasta_url":"https://rest.uniprot.org/uniprotkb/O14593.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14593/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14593"}},"corpus_meta":[{"pmid":"24008419","id":"PMC_24008419","title":"Infernal 1.1: 100-fold faster RNA homology searches.","date":"2013","source":"Bioinformatics (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24008419","citation_count":2652,"is_preprint":false},{"pmid":"21816276","id":"PMC_21816276","title":"mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway.","date":"2011","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21816276","citation_count":992,"is_preprint":false},{"pmid":"20086235","id":"PMC_20086235","title":"Interleukin-1 (IL-1) pathway.","date":"2010","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/20086235","citation_count":778,"is_preprint":false},{"pmid":"9646173","id":"PMC_9646173","title":"Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist.","date":"1998","source":"International reviews of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9646173","citation_count":531,"is_preprint":false},{"pmid":"16244648","id":"PMC_16244648","title":"Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16244648","citation_count":385,"is_preprint":false},{"pmid":"22815045","id":"PMC_22815045","title":"Atrogin-1, MuRF-1, and sarcopenia.","date":"2012","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/22815045","citation_count":301,"is_preprint":false},{"pmid":"11023493","id":"PMC_11023493","title":"PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11023493","citation_count":294,"is_preprint":false},{"pmid":"9819428","id":"PMC_9819428","title":"Delta-1 activation of notch-1 signaling results in HES-1 transactivation.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9819428","citation_count":283,"is_preprint":false},{"pmid":"10753833","id":"PMC_10753833","title":"GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10753833","citation_count":279,"is_preprint":false},{"pmid":"15279787","id":"PMC_15279787","title":"Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex.","date":"2004","source":"DNA repair","url":"https://pubmed.ncbi.nlm.nih.gov/15279787","citation_count":257,"is_preprint":false},{"pmid":"15313461","id":"PMC_15313461","title":"Transferrin receptor 1.","date":"2004","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15313461","citation_count":245,"is_preprint":false},{"pmid":"20421639","id":"PMC_20421639","title":"(1,3)-beta-glucans activate both dectin-1 and NLRP3 inflammasome in human macrophages.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20421639","citation_count":224,"is_preprint":false},{"pmid":"7742552","id":"PMC_7742552","title":"Neutrophils and monocytes express high levels of PU.1 (Spi-1) but not Spi-B.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7742552","citation_count":188,"is_preprint":false},{"pmid":"9785472","id":"PMC_9785472","title":"Interleukin-1.","date":"1998","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9785472","citation_count":176,"is_preprint":false},{"pmid":"20204399","id":"PMC_20204399","title":"CaV2.1 channelopathies.","date":"2010","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20204399","citation_count":175,"is_preprint":false},{"pmid":"22492997","id":"PMC_22492997","title":"DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22492997","citation_count":169,"is_preprint":false},{"pmid":"19804759","id":"PMC_19804759","title":"CDE-1 affects chromosome segregation through uridylation of CSR-1-bound siRNAs.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19804759","citation_count":149,"is_preprint":false},{"pmid":"19037882","id":"PMC_19037882","title":"Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung.","date":"2009","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/19037882","citation_count":145,"is_preprint":false},{"pmid":"15057910","id":"PMC_15057910","title":"Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration.","date":"2004","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15057910","citation_count":141,"is_preprint":false},{"pmid":"9474745","id":"PMC_9474745","title":"Role of PU.1 in hematopoiesis.","date":"1998","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/9474745","citation_count":136,"is_preprint":false},{"pmid":"10072068","id":"PMC_10072068","title":"RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency.","date":"1999","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10072068","citation_count":136,"is_preprint":false},{"pmid":"25231297","id":"PMC_25231297","title":"HIV-1 uncoating is facilitated by dynein and kinesin 1.","date":"2014","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/25231297","citation_count":115,"is_preprint":false},{"pmid":"10790154","id":"PMC_10790154","title":"Modulation of kir4.1 and kir5.1 by hypercapnia and intracellular acidosis.","date":"2000","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10790154","citation_count":110,"is_preprint":false},{"pmid":"11738790","id":"PMC_11738790","title":"Phenotypic spectrum of mutations in DAX-1 and SF-1.","date":"2001","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11738790","citation_count":105,"is_preprint":false},{"pmid":"25306110","id":"PMC_25306110","title":"MacroH2A1.1 and PARP-1 cooperate to regulate transcription by promoting CBP-mediated H2B acetylation.","date":"2014","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25306110","citation_count":98,"is_preprint":false},{"pmid":"18174212","id":"PMC_18174212","title":"Kv7.1 (KCNQ1) properties and channelopathies.","date":"2008","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18174212","citation_count":96,"is_preprint":false},{"pmid":"25628647","id":"PMC_25628647","title":"Regulation of IGF -1 signaling by microRNAs.","date":"2015","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25628647","citation_count":95,"is_preprint":false},{"pmid":"21908431","id":"PMC_21908431","title":"Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21908431","citation_count":89,"is_preprint":false},{"pmid":"12432832","id":"PMC_12432832","title":"Neurofibromatosis 1.","date":"2002","source":"Neurologic clinics","url":"https://pubmed.ncbi.nlm.nih.gov/12432832","citation_count":84,"is_preprint":false},{"pmid":"26048278","id":"PMC_26048278","title":"Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/26048278","citation_count":83,"is_preprint":false},{"pmid":"19074142","id":"PMC_19074142","title":"Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19074142","citation_count":81,"is_preprint":false},{"pmid":"1353982","id":"PMC_1353982","title":"Expression and modification of Hox 2.1 protein in mouse embryos.","date":"1992","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/1353982","citation_count":81,"is_preprint":false},{"pmid":"23018752","id":"PMC_23018752","title":"1q21.1 Microduplication expression in adults.","date":"2012","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23018752","citation_count":79,"is_preprint":false},{"pmid":"12411705","id":"PMC_12411705","title":"Microbial dehalorespiration with 1,1,1-trichloroethane.","date":"2002","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12411705","citation_count":75,"is_preprint":false},{"pmid":"28794034","id":"PMC_28794034","title":"An Epstein-Barr Virus MicroRNA Blocks Interleukin-1 (IL-1) Signaling by Targeting IL-1 Receptor 1.","date":"2017","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/28794034","citation_count":74,"is_preprint":false},{"pmid":"9987673","id":"PMC_9987673","title":"Thrombospondin-1, PECAM-1, and regulation of angiogenesis.","date":"1999","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/9987673","citation_count":73,"is_preprint":false},{"pmid":"23500036","id":"PMC_23500036","title":"mRNA degradation by the endoribonuclease Regnase-1/ZC3H12a/MCPIP-1.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23500036","citation_count":72,"is_preprint":false},{"pmid":"11483518","id":"PMC_11483518","title":"Regulation of BOB.1/OBF.1 stability by SIAH.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11483518","citation_count":72,"is_preprint":false},{"pmid":"11853016","id":"PMC_11853016","title":"Expression of nicotinamide N-methyltransferase (E.C. 2.1.1.1) in the Parkinsonian brain.","date":"2002","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11853016","citation_count":71,"is_preprint":false},{"pmid":"36696089","id":"PMC_36696089","title":"Rapid Access to 2-Substituted Bicyclo[1.1.1]pentanes.","date":"2023","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/36696089","citation_count":68,"is_preprint":false},{"pmid":"16339961","id":"PMC_16339961","title":"Regulation of ROMK (Kir1.1) channels: new mechanisms and aspects.","date":"2006","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16339961","citation_count":58,"is_preprint":false},{"pmid":"24029427","id":"PMC_24029427","title":"Chromosome 2q31.1 associates with ESRD in women with type 1 diabetes.","date":"2013","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/24029427","citation_count":57,"is_preprint":false},{"pmid":"30213788","id":"PMC_30213788","title":"Nedd4-Binding Protein 1 and TNFAIP3-Interacting Protein 1 Control MHC-1 Display in Neuroblastoma.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30213788","citation_count":54,"is_preprint":false},{"pmid":"10713349","id":"PMC_10713349","title":"PU.1 expression in microglia.","date":"2000","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/10713349","citation_count":52,"is_preprint":false},{"pmid":"33951726","id":"PMC_33951726","title":"Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33951726","citation_count":51,"is_preprint":false},{"pmid":"10597240","id":"PMC_10597240","title":"Association of Pur alpha and E2F-1 suppresses transcriptional activity of E2F-1.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10597240","citation_count":51,"is_preprint":false},{"pmid":"12489180","id":"PMC_12489180","title":"TGF beta-1 downregulates DMP-1 and DSPP in odontoblasts.","date":"2002","source":"Connective tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/12489180","citation_count":50,"is_preprint":false},{"pmid":"18324520","id":"PMC_18324520","title":"APE1/Ref-1 regulates PTEN expression mediated by Egr-1.","date":"2008","source":"Free radical research","url":"https://pubmed.ncbi.nlm.nih.gov/18324520","citation_count":50,"is_preprint":false},{"pmid":"15371551","id":"PMC_15371551","title":"Predicting genes expressed via -1 and +1 frameshifts.","date":"2004","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/15371551","citation_count":50,"is_preprint":false},{"pmid":"18056379","id":"PMC_18056379","title":"Interactions between Idd5.1/Ctla4 and other type 1 diabetes genes.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18056379","citation_count":49,"is_preprint":false},{"pmid":"32222817","id":"PMC_32222817","title":"Skeletal muscle CaV1.1 channelopathies.","date":"2020","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32222817","citation_count":48,"is_preprint":false},{"pmid":"16236793","id":"PMC_16236793","title":"Class II histone deacetylases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RFXANK.","date":"2005","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/16236793","citation_count":48,"is_preprint":false},{"pmid":"35624087","id":"PMC_35624087","title":"PI(18:1/18:1) is a SCD1-derived lipokine that limits stress signaling.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35624087","citation_count":48,"is_preprint":false},{"pmid":"16297876","id":"PMC_16297876","title":"PKCalpha expression regulated by Elk-1 and MZF-1 in human HCC cells.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16297876","citation_count":48,"is_preprint":false},{"pmid":"11406616","id":"PMC_11406616","title":"p21Cip-1/SDI-1/WAF-1 gene is involved in chondrogenic differentiation of ATDC5 cells in vitro.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11406616","citation_count":44,"is_preprint":false},{"pmid":"31092016","id":"PMC_31092016","title":"Inhibition of CHK 1 (Checkpoint Kinase 1) Elicits Therapeutic Effects in Pulmonary Arterial Hypertension.","date":"2019","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31092016","citation_count":42,"is_preprint":false},{"pmid":"18814180","id":"PMC_18814180","title":"Elk-1, CREB, and MKP-1 regulate Egr-1 expression in gonadotropin-releasing hormone stimulated gonadotrophs.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18814180","citation_count":41,"is_preprint":false},{"pmid":"22696442","id":"PMC_22696442","title":"Macrophage dectin-1 expression is controlled by leukotriene B4 via a GM-CSF/PU.1 axis.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22696442","citation_count":41,"is_preprint":false},{"pmid":"23547809","id":"PMC_23547809","title":"Sirtuin-1 and HIV-1: an overview.","date":"2013","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/23547809","citation_count":40,"is_preprint":false},{"pmid":"11463838","id":"PMC_11463838","title":"Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome.","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11463838","citation_count":40,"is_preprint":false},{"pmid":"10412368","id":"PMC_10412368","title":"DAX-1, an 'antitestis' gene.","date":"1999","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/10412368","citation_count":39,"is_preprint":false},{"pmid":"35759692","id":"PMC_35759692","title":"On-DNA Hydroalkylation to Introduce Diverse Bicyclo[1.1.1]pentanes and Abundant Alkyls via Halogen Atom Transfer.","date":"2022","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/35759692","citation_count":39,"is_preprint":false},{"pmid":"24394957","id":"PMC_24394957","title":"miRNA-1 regulates endothelin-1 in diabetes.","date":"2014","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24394957","citation_count":39,"is_preprint":false},{"pmid":"31291500","id":"PMC_31291500","title":"Reactions of 2-Aryl-1,3-Dithianes and [1.1.1]Propellane.","date":"2019","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/31291500","citation_count":38,"is_preprint":false},{"pmid":"8579881","id":"PMC_8579881","title":"An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane).","date":"1995","source":"Human & experimental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/8579881","citation_count":37,"is_preprint":false},{"pmid":"29333442","id":"PMC_29333442","title":"Characterisation of Casein Kinase 1.1 in Leishmania donovani Using the CRISPR Cas9 Toolkit.","date":"2017","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/29333442","citation_count":37,"is_preprint":false},{"pmid":"28821586","id":"PMC_28821586","title":"Ku70 Senses HTLV-1 DNA and Modulates HTLV-1 Replication.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28821586","citation_count":36,"is_preprint":false},{"pmid":"10744748","id":"PMC_10744748","title":"Gab-1-mediated IGF-1 signaling in IRS-1-deficient 3T3 fibroblasts.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10744748","citation_count":36,"is_preprint":false},{"pmid":"15671479","id":"PMC_15671479","title":"Diabetes outfoxed by GLP-1?","date":"2005","source":"Science's STKE : signal transduction knowledge environment","url":"https://pubmed.ncbi.nlm.nih.gov/15671479","citation_count":35,"is_preprint":false},{"pmid":"18297547","id":"PMC_18297547","title":"Multimerin 1.","date":"2008","source":"Platelets","url":"https://pubmed.ncbi.nlm.nih.gov/18297547","citation_count":34,"is_preprint":false},{"pmid":"10803838","id":"PMC_10803838","title":"Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B.","date":"2000","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10803838","citation_count":33,"is_preprint":false},{"pmid":"22500837","id":"PMC_22500837","title":"The 1-1-1 fallacy.","date":"2012","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22500837","citation_count":32,"is_preprint":false},{"pmid":"12618906","id":"PMC_12618906","title":"Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II.","date":"2003","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12618906","citation_count":32,"is_preprint":false},{"pmid":"7655733","id":"PMC_7655733","title":"Multiple endocrine neoplasia type 1 (MEN 1) revisited.","date":"1995","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7655733","citation_count":32,"is_preprint":false},{"pmid":"40136024","id":"PMC_40136024","title":"Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants.","date":"2025","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/40136024","citation_count":30,"is_preprint":false},{"pmid":"27481513","id":"PMC_27481513","title":"Neuropilin-1 (NRP-1)/GIPC1 pathway mediates glioma progression.","date":"2016","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27481513","citation_count":30,"is_preprint":false},{"pmid":"15964851","id":"PMC_15964851","title":"Identification of the ankyrin repeat proteins ANKRA and RFXANK as novel partners of class IIa histone deacetylases.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15964851","citation_count":30,"is_preprint":false},{"pmid":"21078302","id":"PMC_21078302","title":"Glutaredoxin-1 regulates TRAF6 activation and the IL-1 receptor/TLR4 signalling.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21078302","citation_count":30,"is_preprint":false},{"pmid":"28546511","id":"PMC_28546511","title":"The NANCI-Nkx2.1 gene duplex buffers Nkx2.1 expression to maintain lung development and homeostasis.","date":"2017","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/28546511","citation_count":30,"is_preprint":false},{"pmid":"30444039","id":"PMC_30444039","title":"Translocation and activation of sphingosine kinase 1 by ceramide-1-phosphate.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30444039","citation_count":28,"is_preprint":false},{"pmid":"10725724","id":"PMC_10725724","title":"Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10725724","citation_count":28,"is_preprint":false},{"pmid":"21695196","id":"PMC_21695196","title":"Subtype specific elevated expression of hyaluronidase-1 (HYAL-1) in epithelial ovarian cancer.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21695196","citation_count":28,"is_preprint":false},{"pmid":"24276247","id":"PMC_24276247","title":"Enhanced expression of transferrin receptor 1 contributes to oncogenic signalling by sphingosine kinase 1.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24276247","citation_count":28,"is_preprint":false},{"pmid":"20414676","id":"PMC_20414676","title":"The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population.","date":"2010","source":"European journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/20414676","citation_count":27,"is_preprint":false},{"pmid":"8804025","id":"PMC_8804025","title":"Molecular analysis of the lissencephaly gene 1 (LIS-1) in medulloblastomas.","date":"1996","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/8804025","citation_count":27,"is_preprint":false},{"pmid":"26198631","id":"PMC_26198631","title":"Regulation of Yin Yang 1 by Tyrosine Phosphorylation.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26198631","citation_count":26,"is_preprint":false},{"pmid":"21978893","id":"PMC_21978893","title":"9-1-1: PCNA's specialized cousin.","date":"2011","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21978893","citation_count":25,"is_preprint":false},{"pmid":"29363163","id":"PMC_29363163","title":"LncRNA-RP11-714G18.1 suppresses vascular cell migration via directly targeting LRP2BP.","date":"2017","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29363163","citation_count":25,"is_preprint":false},{"pmid":"28650468","id":"PMC_28650468","title":"MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28650468","citation_count":24,"is_preprint":false},{"pmid":"39282390","id":"PMC_39282390","title":"Neutralization and Stability of JN.1-derived LB.1, KP.2.3, KP.3 and KP.3.1.1 Subvariants.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39282390","citation_count":24,"is_preprint":false},{"pmid":"23034181","id":"PMC_23034181","title":"POS-1 and GLD-1 repress glp-1 translation through a conserved binding-site cluster.","date":"2012","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/23034181","citation_count":24,"is_preprint":false},{"pmid":"19825991","id":"PMC_19825991","title":"PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation.","date":"2009","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/19825991","citation_count":24,"is_preprint":false},{"pmid":"25845046","id":"PMC_25845046","title":"PDX-1 (pancreatic/duodenal homeobox-1 protein 1).","date":"2014","source":"Pathologica","url":"https://pubmed.ncbi.nlm.nih.gov/25845046","citation_count":23,"is_preprint":false},{"pmid":"28708824","id":"PMC_28708824","title":"Tex19.1 promotes Spo11-dependent meiotic recombination in mouse spermatocytes.","date":"2017","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28708824","citation_count":23,"is_preprint":false},{"pmid":"29016962","id":"PMC_29016962","title":"An Apple Protein Kinase MdSnRK1.1 Interacts with MdCAIP1 to Regulate ABA Sensitivity.","date":"2017","source":"Plant & cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29016962","citation_count":22,"is_preprint":false},{"pmid":"19570917","id":"PMC_19570917","title":"Caenorhabditis elegans FOS-1 and JUN-1 regulate plc-1 expression in the spermatheca to control ovulation.","date":"2009","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/19570917","citation_count":22,"is_preprint":false},{"pmid":"29768134","id":"PMC_29768134","title":"mTOR signalling: jack-of-all-trades 1.","date":"2018","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/29768134","citation_count":21,"is_preprint":false},{"pmid":"21302086","id":"PMC_21302086","title":"Location of theSas-1 locus on mouse chromosome 1.","date":"1978","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/21302086","citation_count":21,"is_preprint":false},{"pmid":"34038245","id":"PMC_34038245","title":"Maresin-1 induces cardiomyocyte hypertrophy through IGF-1 paracrine pathway.","date":"2021","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/34038245","citation_count":20,"is_preprint":false},{"pmid":"23139844","id":"PMC_23139844","title":"Sigma-1 receptor agonists directly inhibit Nav1.2/1.4 channels.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23139844","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47602,"output_tokens":2216,"usd":0.088023,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9241,"output_tokens":2605,"usd":0.055665,"stage2_stop_reason":"end_turn"},"total_usd":0.143688,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"RFXANK (RFX-B) was identified as the smallest subunit of the heterotrimeric RFX complex. It contains three ankyrin repeats but no known DNA-binding domain, and its loss-of-function mutations are responsible for the predominant bare lymphocyte syndrome (BLS) complementation group B, characterized by absence of MHC class II transcription.\",\n      \"method\": \"Protein purification, sequencing, complementation assay in BLS patient cell lines\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — protein purified and sequenced, complementation assays in disease cell lines, replicated across studies\",\n      \"pmids\": [\"10072068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"RFXANK ankyrin repeats mediate simultaneous interactions with RFXAP and CIITA on two opposite faces of the ankyrin repeat domain. RFXAP binding requires two separate surfaces on RFXANK, one located in the ankyrin groove. A BLS patient mutation (FZA) specifically disrupts the RFXAP-binding surface in the ankyrin groove without affecting CIITA binding.\",\n      \"method\": \"Computational modeling of RFXANK, site-directed alanine mutagenesis of variable ankyrin residues, in vitro and in vivo binding assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with both in vitro and in vivo binding studies, structural modeling validated by functional assays, single lab\",\n      \"pmids\": [\"11463838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Novel mutations in RFX-B (RFXANK) were identified in BLS patient fibroblasts. Unlike RFX5- and RFXAP-deficient cells, exogenous CIITA partially rescued MHC class II (HLA-DR, HLA-DP), MHC class I, beta2-microglobulin, and invariant chain expression in RFX-B-deficient cells, suggesting CIITA can partially override RFX-B deficiency. Wild-type RFX-B expression fully reverted all noted deficiencies.\",\n      \"method\": \"Mutation analysis, CIITA transfection rescue experiments, MHC reporter assays in patient-derived fibroblasts\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complementation and rescue experiments in patient cell lines, two orthogonal methods, single lab\",\n      \"pmids\": [\"10725724\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Two novel RFXANK missense mutations (D121V and Y224A) were characterized. The D121V mutant was unable to form the RFX complex, indicating D121 is required for RFXAP binding. The Y224A mutant formed an RFX complex that bound normally to the MHC II promoter but failed to transactivate MHC class II, indicating that an aromatic ring at position 224 is needed for a function beyond promoter binding—likely interaction with an additional unknown protein via the fourth ankyrin repeat.\",\n      \"method\": \"Site-directed mutagenesis, protein interaction assays, DNA binding assays, MHC II expression analysis in patient cells\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with in vitro protein interaction and DNA binding assays, functional readout of MHC II expression, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"12618906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Class IIa HDACs (HDAC4 and HDAC5) physically associate with RFXANK (RFX-B/Tvl-1/ANKRA1) through its ankyrin repeat domain. HDAC4 has two RFXANK-binding sites (residues 118-279 and 448-666). Through this association, HDAC4 and HDAC5 repress MHC II promoter activation and endogenous HLA-DRA gene expression induced by CIITA. Phosphorylation of class II HDACs by CaMK results in CRM1-dependent nuclear export of HDAC/RFXANK complexes.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, ankyrin repeat interaction mapping, MHC II promoter reporter assays, HLA-DRA expression assays, CaMK phosphorylation and nuclear export assays\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated independently in two labs (McKinsey et al. and Wang et al., same year), reciprocal interaction mapping, functional promoter assays, and signal-responsive nuclear export mechanism established\",\n      \"pmids\": [\"16236793\", \"15964851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"RFXANK interacts with class IIa HDAC4 through its ankyrin repeat domain. Two RFXANK-binding sites were mapped on HDAC4 (residues 118-279 and 448-666). HDAC4 also interacted with CIITA. HDAC4 and homologs repressed MHC II expression, identifying RFXANK and CIITA as novel targets of class IIa HDACs.\",\n      \"method\": \"Yeast two-hybrid screen (HDAC4 as bait), co-immunoprecipitation, deletion mapping, MHC II expression assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus co-IP with functional MHC II expression assays, single lab, consistent with independent report\",\n      \"pmids\": [\"15964851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RFXANK gene mutations (predominantly a 26-bp founder deletion, I5E6-25_I5E6+1) account for two-thirds of all MHC class II deficiency cases. Patients have absence of MHC class II molecule expression, impaired antigen presentation to CD4+ T cells, and combined immunodeficiency. Hematopoietic stem cell transplantation restores near-normal immune function, establishing RFXANK as essential for MHC II expression in the immune system.\",\n      \"method\": \"Genetic analysis of 35 patients, immunological phenotyping, HSCT outcome analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Strong — large patient cohort with genetic and immunological characterization, but primarily clinical/genetic rather than direct mechanistic biochemical assay\",\n      \"pmids\": [\"21908431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The 752delG-25 (26-bp deletion) mutation in RFXANK is a founder mutation of North African origin responsible for the majority of MHC class II deficiency group B patients. This mutation eliminates RFXANK function required for RFX complex assembly and MHC II transcription.\",\n      \"method\": \"Mutation analysis in 20 patients, haplotype analysis for founder effect, functional complementation\",\n      \"journal\": \"Immunogenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic analysis across multiple unrelated families, haplotype confirmation of founder effect, functional data from complementation studies in related papers\",\n      \"pmids\": [\"10803838\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RFXANK (RFX-B) is a subunit of the heterotrimeric RFX transcription factor complex that nucleates assembly of multiple transcription factors (including RFX5, RFXAP, and CIITA) on MHC class II gene promoters; its ankyrin repeat domain mediates simultaneous binding of RFXAP and CIITA on opposite faces, and class IIa HDACs (HDAC4/5) associate with these ankyrin repeats to repress MHC II transcription in a CaMK-phosphorylation/nuclear-export-dependent manner, while loss-of-function RFXANK mutations cause bare lymphocyte syndrome by abolishing MHC II expression and antigen presentation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RFXANK (RFX-B) is the smallest subunit of the heterotrimeric RFX transcription factor complex that governs MHC class II gene expression, and loss-of-function mutations in it cause the predominant complementation group B of bare lymphocyte syndrome through abolition of MHC class II transcription [#0, #6]. Although it lacks a DNA-binding domain, its three ankyrin repeats serve as a scaffold that simultaneously engages RFXAP and CIITA on opposite faces of the ankyrin repeat domain; RFXAP binding depends on a surface within the ankyrin groove, and patient mutations such as D121V abolish RFX complex assembly by disrupting RFXAP binding [#1, #3]. A separate function maps to the fourth ankyrin repeat: the Y224A mutant assembles an RFX complex that binds the MHC II promoter normally yet fails to transactivate, defining a transactivation step beyond promoter occupancy [#3]. RFXANK is also a target of negative regulation, as class IIa HDACs (HDAC4 and HDAC5) associate with its ankyrin repeats and with CIITA to repress CIITA-induced MHC II and endogenous HLA-DRA expression, a repression relieved when CaMK phosphorylation drives CRM1-dependent nuclear export of the HDAC/RFXANK complex [#4, #5]. Functionally, RFXANK deficiency in patients eliminates MHC class II surface expression and CD4+ T cell antigen presentation, a defect correctable by hematopoietic stem cell transplantation [#6].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established the molecular identity of the BLS group B gene by purifying RFXANK as the smallest RFX subunit, linking an ankyrin-repeat protein lacking DNA-binding activity to loss of MHC class II transcription.\",\n      \"evidence\": \"Protein purification, sequencing, and complementation in BLS patient cell lines\",\n      \"pmids\": [\"10072068\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how a DNA-binding-deficient subunit contributes to promoter function\", \"Interaction surfaces with other RFX subunits not yet mapped\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined the genetic basis of group B disease by identifying a North African founder deletion as the major RFXANK lesion abolishing RFX complex assembly.\",\n      \"evidence\": \"Mutation and haplotype analysis across patients with functional complementation\",\n      \"pmids\": [\"10803838\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Founder effect is genetic/epidemiological rather than direct biochemical proof of the assembly defect\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Revealed that RFXANK deficiency is distinct from RFX5/RFXAP loss, since exogenous CIITA can partially restore MHC expression, implicating RFXANK in a CIITA-influenced step.\",\n      \"evidence\": \"CIITA transfection rescue and MHC reporter assays in patient fibroblasts\",\n      \"pmids\": [\"10725724\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of partial CIITA override not defined\", \"Single lab, patient-cell-based readouts\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved the architectural role of the ankyrin repeats, showing RFXANK uses opposite faces to bind RFXAP and CIITA simultaneously and that a patient mutation disrupts only the RFXAP-binding groove.\",\n      \"evidence\": \"Computational modeling, alanine-scanning mutagenesis, in vitro and in vivo binding assays\",\n      \"pmids\": [\"11463838\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No experimental structure of the assembled complex\", \"Stoichiometry on the promoter not determined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Separated RFXANK's assembly function from its transactivation function via two missense mutants, showing D121 is needed for RFXAP binding while Y224 is dispensable for promoter binding but required for transactivation.\",\n      \"evidence\": \"Site-directed mutagenesis, protein interaction and DNA binding assays, MHC II expression analysis in patient cells\",\n      \"pmids\": [\"12618906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The additional protein inferred to bind the fourth ankyrin repeat was not identified\", \"Direct transactivation partner remains uncharacterized\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified RFXANK as a regulatory target by showing class IIa HDAC4/HDAC5 bind its ankyrin repeats and repress CIITA-driven MHC II transcription in a CaMK-phosphorylation/CRM1-export-dependent manner.\",\n      \"evidence\": \"Yeast two-hybrid, co-immunoprecipitation, interaction mapping, promoter and HLA-DRA expression assays, CaMK/nuclear export assays\",\n      \"pmids\": [\"16236793\", \"15964851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological signals controlling CaMK-driven repression in immune cells not defined\", \"Whether HDAC binding competes directly with RFXAP/CIITA on the ankyrin surface not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Consolidated RFXANK as the dominant cause of MHC class II deficiency and demonstrated that the resulting immunodeficiency is correctable, confirming RFXANK is essential for immune MHC II expression.\",\n      \"evidence\": \"Genetic and immunological analysis of 35 patients with HSCT outcome data\",\n      \"pmids\": [\"21908431\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Clinical/genetic rather than direct biochemical mechanism\", \"Does not address tissue-specific roles outside the immune system\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The identity of the protein bound by the fourth ankyrin repeat that mediates RFXANK-dependent transactivation beyond promoter occupancy remains unknown.\",\n      \"evidence\": \"Inferred from the Y224A transactivation-defective phenotype\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No candidate partner for the transactivation step identified\", \"No structural model of the RFXANK transactivation interface\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 3]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [1, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 3]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"complexes\": [\"RFX complex (RFX5-RFXAP-RFXANK)\"],\n    \"partners\": [\"RFXAP\", \"CIITA\", \"RFX5\", \"HDAC4\", \"HDAC5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}